ElucidVivo A.3 vs iPredict Eye Screening
AI Verdict
Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your practice requires highly detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to precisely stratify atherosclerosis patients. This tool is ideal for cardiologists, radiologists, and vascular surgeons needing to optimize treatment decisions based on objective measurements of lipid-rich necrotic core, matrix, and calcifications, validated against histology.
View ElucidVivo A.3 →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your primary care clinic or telemedicine service needs a fast, non-invasive, and accurate AI-powered tool for early detection of common retinal diseases like AMD, DR, and Glaucoma. This platform is best suited for broad patient screening and integrated risk prediction for systemic conditions such as stroke and heart attack, providing rapid results in under five minutes.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ElucidVivo A.3 | iPredict Eye Screening |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud and on-premise secure deployment. | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B (iPredict Eye Screening) emphasizes ease of operation with an advanced touchscreen interface and fast results, making it highly accessible for primary care settings and telemedicine. Tool A (ElucidVivo A.3), while powerful for specialists, appears to have a more complex interface focused on detailed 3D visualization and quantitative analysis.
Clinical Value
ElucidVivo A.3Tool A (ElucidVivo A.3) offers deep, quantitative analysis of arterial plaque composition and stability from CT angiography, validated against histology, and derives fractional flow reserve (FFRct). This provides highly specific and validated diagnostic insights for atherosclerosis patient stratification and treatment optimization, which is a more advanced diagnostic capability compared to Tool B's broader screening focus.
Pricing & Value
iPredict Eye ScreeningTool B (iPredict Eye Screening) provides more transparency regarding its pricing model, detailing a per-patient SaaS model with an estimated cost range of $10-$20. This allows potential customers to better assess its value proposition and budget compared to Tool A, which only states 'contact for pricing.'
Enterprise Readiness
iPredict Eye ScreeningBoth tools integrate with existing healthcare systems, but Tool B (iPredict Eye Screening) explicitly states HIPAA compliance and its cloud-based deployment is accessible across primary care, clinics, hospitals, and telemedicine. This broader accessibility and explicit compliance statement suggest greater flexibility and readiness for diverse enterprise environments compared to Tool A, which implies HIPAA compliance but is less explicit about deployment flexibility.
Innovation
ElucidVivo A.3Tool A (ElucidVivo A.3)'s ability to objectively quantify specific arterial plaque components (Lipid-Rich Necrotic Core, matrix, calcifications) and derive fractional flow reserve (FFRct) from CT images, validated against ground-truth histology, represents a significant advancement in diagnostic imaging and cardiovascular risk assessment. While Tool B's multi-disease screening and systemic risk prediction are innovative, Tool A's deep, quantitative diagnostic capability pushes the boundaries of medical imaging analysis more profoundly.
Support & Docs
TieNeither the provided structured facts nor publicly available information from web searches offer specific details regarding the level of support or documentation provided for either ElucidVivo A.3 or iPredict Eye Screening. Therefore, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ElucidVivo A.3 | iPredict Eye Screening |
|---|---|---|
| Tool Name | ElucidVivo A.3 | iPredict Eye Screening |
| Company | Elucid Bioimaging | iHealthScreen |
| Primary Focus | AI-powered medical image analysis for quantitative analysis of arterial plaque composition and stability from CT angiography, aiding in atherosclerosis patient stratification and treatment decisions. | AI-powered screening tool for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma, with risk prediction for systemic diseases like stroke and heart attack. |
| Key Analytical/Screening Capabilities | AI-powered quantitative analysis of arterial plaque (LRNC, matrix, calcifications), 3D visualization of highlighted vessels, rotatable curved MPR vessel views, FFRct derivation, validated on histology. | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients. |
| Target Specialties | Cardiology, Radiology, Vascular Surgery | Family Medicine, Internal Medicine, Ophthalmology |
Videos
Demos, reviews, and walkthroughs featuring ElucidVivo A.3 and iPredict Eye Screening.